Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Knee length vs thigh length graduated compression stockings Deep vein thrombosis (Fixed‐effect analysis) Venous duplex scan, contrast venography and fibrinogen uptake scan · patients with prevention of deep vein thrombosis1 Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in… (2012) · Cochrane | OR 1.55 [0.78, 3.07] | 3 studies · 496 participants | Very low |
Knee length vs thigh length graduated compression stockings Deep vein thrombosis (Random‐effects analysis) Venous duplex scan, contrast venography and fibrinogen uptake scan · patients with prevention of deep vein thrombosis1 Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in… (2012) · Cochrane | OR 1.32 [0.43, 4.06] | 3 studies · 496 participants | Very low |
Knee length vs thigh length graduated compression stockings Deep vein thrombosis (Risk Difference) Venous duplex scan, contrast venography and fibrinogen uptake scan · patients with prevention of deep vein thrombosis1 Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in… (2012) · Cochrane | no estimate extracted | 3 studies · 496 participants | Very low |
Intervention NR Death from any cause ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | 4 studies · 264 participants | Moderate |
Intervention NR Costs ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR HbA1c ( · patients with diabetes mellitus Cinnamon for diabetes mellitus (2012) · Cochrane | no estimate extracted | 6 studies · 405 participants | Moderate |
Doxycycline+Rifampicin vs Doxycycline+Streptomycin total treatment failure · patients with human Brucellosis Antibiotics for treating human brucellosis (2012) · Cochrane | RR 1.91 [1.07, 3.42] | 7 studies · 567 participants | Moderate |
Doxycycline+Rifampicin vs Doxycycline+Streptomycin Minor adverse drug reactions · patients with human Brucellosis Antibiotics for treating human brucellosis (2012) · Cochrane | RR 1.38 [0.99, 1.92] | 5 studies · 473 participants | Low |
Doxycycline+Rifampicin vs Quinolones+Rifampicin total treatment failure · patients with human Brucellosis Antibiotics for treating human brucellosis (2012) · Cochrane | OR 0.94 [0.45, 1.98] | 3 studies · 181 participants | Moderate |
Doxycycline+Rifampicin vs Quinolones+Rifampicin Minor adverse drug reactions · patients with human Brucellosis Antibiotics for treating human brucellosis (2012) · Cochrane | RR 1.8 [0.78, 4.18] | 4 studies · 296 participants | Low |
Doxycycline+Streptomycin vs Doxycycline+Gentamycin total treatment failure · patients with human Brucellosis Antibiotics for treating human brucellosis (2012) · Cochrane | OR 1.85 [0.84, 4.08] | 2 studies · 345 participants | Low |
Doxycycline+Streptomycin vs Doxycycline+Gentamycin Minor adverse drug reactions · patients with human Brucellosis Antibiotics for treating human brucellosis (2012) · Cochrane | RR 0.85 [0.6, 1.22] | 2 studies · 345 participants | Very low |
TDF+ FTC vs placebo HIV infection · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers) Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals (2012) · Cochrane | RR 0.49 [0.28, 0.85] | 4 studies · 8813 participants | Moderate |
TDF+ FTC vs placebo Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers) Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals (2012) · Cochrane | RR 1 [0.83, 1.19] | 3 studies · 6862 participants | Moderate |
TDF vs placebo HIV infection · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers) Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals (2012) · Cochrane | RR 0.33 [0.2, 0.55] | 2 studies · 4027 participants | Moderate |
TDF vs placebo Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers) Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals (2012) · Cochrane | RR 1.03 [0.79, 1.33] | 1 study · 3168 participants | Moderate |
Technology‐mediated psychoeducation vs standard care intervention Compliance/satisfaction: leaving the study early ‐ any reason · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 1.24 [0.81, 1.88] | 2 studies · 116 participants | Very low |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Global state: not improved ‐ short‐term GAF · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 1.15 [0.86, 1.54] | 1 study · 56 participants | Low |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Knowledge/insight: not improved ITAQ · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 1 [0.76, 1.31] | 1 study · 56 participants | Low |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Quality of life · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Needs · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Social support · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Technology‐mediated psychoeducation vs standard care intervention Mental state: not improved ‐ short‐term BPRS · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 0.75 [0.56, 1] | 1 study · 84 participants | Low |
Technology‐mediated psychoeducation vs standard care intervention Global state: not improved ‐ short‐term GAF · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 1.08 [0.82, 1.42] | 1 study · 84 participants | Low |
Technology‐mediated psychoeducation vs standard care intervention Knowledge/insight · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Technology‐mediated psychoeducation vs standard care intervention Quality of life · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Technology‐mediated psychoeducation vs standard care intervention Needs · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | no estimate extracted | 0 studies · 0 participants | Ungraded |
Technology‐mediated psychoeducation vs standard care intervention Social support Social Network Interview · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 0.42 [0.04, 0.8] | 1 study · 60 participants | Ungraded |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Compliance/satisfaction: medication ‐ not compliant ‐ long‐term · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 0.45 [0.27, 0.77] | 1 study · 71 participants | Very low |
Technology‐mediated psychoeducation + standard care intervention vs standard care intervention Mental state: not improved ‐ short‐term BPRS · patients with people with schizophrenia Information and communication technology in patient education and support for people with schizophrenia (2012) · Cochrane | RR 0.86 [0.63, 1.19] | 1 study · 56 participants | Low |
Black cohosh vs placebo Vasomotor symptoms: daily hot flush frequency · patients with menopausal symptoms Black cohosh (Cimicifuga spp.) for menopausal symptoms (2012) · Cochrane | no estimate extracted | 3 studies · 393 participants | Moderate |
Black cohosh vs placebo Vasomotor symptoms: hot flush intensity · patients with menopausal symptoms Black cohosh (Cimicifuga spp.) for menopausal symptoms (2012) · Cochrane | no estimate extracted | 3 studies · 214 participants | Moderate |
Black cohosh vs placebo Vasomotor symptoms: night sweats · patients with menopausal symptoms Black cohosh (Cimicifuga spp.) for menopausal symptoms (2012) · Cochrane | no estimate extracted | 1 study · 164 participants | Moderate |
Black cohosh vs placebo Menopausal Symptom Score · patients with menopausal symptoms Black cohosh (Cimicifuga spp.) for menopausal symptoms (2012) · Cochrane | no estimate extracted | 4 studies · 357 participants | Moderate |
Black cohosh vs placebo Adverse events · patients with menopausal symptoms Black cohosh (Cimicifuga spp.) for menopausal symptoms (2012) · Cochrane | RR 1.04 [0.82, 1.32] | 2 studies · 344 participants | Low |
Intervention NR Primary outcome: Mortality · Adults (over 18 years) with requirement for an ERCP procedure with diagnostic intent Sedative techniques for endoscopic retrograde cholangiopancreatography (2012) · Cochrane | no estimate extracted | 4 studies · 510 participants | Moderate |
Intervention NR Primary Outcome: Hypoxaemia · Adults (over 18 years) with requirement for an ERCP procedure with diagnostic intent Sedative techniques for endoscopic retrograde cholangiopancreatography (2012) · Cochrane | no estimate extracted | 4 studies · 510 participants | Moderate |
Intervention NR Primary Outcome: Hypotension · Adults (over 18 years) with requirement for an ERCP procedure with diagnostic intent Sedative techniques for endoscopic retrograde cholangiopancreatography (2012) · Cochrane | no estimate extracted | 4 studies · 510 participants | Moderate |
Intervention NR Primary outcome: Failure to complete procedure (due to sedation‐related problems) · Adults (over 18 years) with requirement for an ERCP procedure with diagnostic intent Sedative techniques for endoscopic retrograde cholangiopancreatography (2012) · Cochrane | no estimate extracted | 3 studies · 360 participants | Moderate |
Intervention NR Secondary outcome: Recovery · Adults (over 18 years) with requirement for an ERCP procedure with diagnostic intent Sedative techniques for endoscopic retrograde cholangiopancreatography (2012) · Cochrane | no estimate extracted | 3 studies · 359 participants | Moderate |
Intervention NR Death (all cause) · HIV infected adults who meet the WHO criteria for commencing antiretroviral treatment. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV (2012) · Cochrane | RR 0.5 [0.05, 5.46] | 1 study · 487 participants | Low |
Intervention NR Proportion of patients achieving and maintaining undetectable viral load, e.g. less than 400 copies/ml · HIV infected adults who meet the WHO criteria for commencing antiretroviral treatment. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV (2012) · Cochrane | RR 1.16 | 1 study · 487 participants | Low |
Intervention NR Proportion of patients achieving and maintaining undetectable viral load, e.g. less than 50 copies/ml · HIV infected adults who meet the WHO criteria for commencing antiretroviral treatment. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV (2012) · Cochrane | RR 1.13 [1.02, 1.25] | 1 study · 487 participants | Low |
Intervention NR CD4+ count · HIV infected adults who meet the WHO criteria for commencing antiretroviral treatment. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pain 10‐cm VAS scale (median · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | no estimate extracted | 2 studies · 524 participants | Moderate |
Intervention NR Function WOMAC function (range 0 to 10) (median · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | no estimate extracted | 2 studies · 517 participants | Moderate |
Intervention NR Minimum joint space width ( · participants with osteoarthritis of the knee or hip Doxycycline for osteoarthritis of the knee or hip (2012) · Cochrane | no estimate extracted | 1 study · 361 participants | Moderate |